TCT Key Events

Print This Page

Tell a Colleague

Prescribing Information

About ANGIOMAX

Clinical Information

About PCI

Bleeding – a Predictor
of Mortality

About HIT/HITTS

Removal of the Femoral
Arterial Catheter

Medical Information

Helpful Resources

ANGIOMAX Key Events at:

Mode of Action Video

See a vivid demonstration of ANGIOMAX in action. Watch ANGIOMAX: Thrombin-Specific Inhibition for Preventing Thrombosis and Thrombin-Mediated Platelet Activation.

Key Events at TCT 2007

Monday, October 22, 2007

Oral Presentations

10:21 AM (Room 145 AB) TCT-54	RENAL: “Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing Percutaneous Coronary Intervention and being treated with Bivalirudin vs Heparin plus a Glycoprotein IIb/IIIa Inhibitor: Results from the Randomized ACUITY Trial” (Mehran, et al)
10:36 AM (Room 145 AB) TCT-55	THIENOPYRIDINE USE IN ACUITY: “Clopidogrel Pretreatment Versus Clopidogrel Exposure Prior to PCI in the ACUITY Trial: Does it Really Matter?” (Steinhubl, et al)
10:51 AM (Room 145 AB) TCT-56	ANEMIA: “Impact of Anemia on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention” (Manoukian, et al)
5:19 PM (Room 151 AB) TCT-102	PCI: “Safety and Efficacy of Bivalirudin with and without Glycoprotein IIb/IIIa Inhibitors in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: One Year Results from the Randomized ACUITY Trial” (White, et al)
Tuesday, October 23, 2007
Oral Presentations
5:02 PM (Room 151 AB) TCT-137	GPI SWITCH: “Safety and Efficacy of Switching from Either Unfractionated Heparin or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with NSTE ACS Managed with an Invasive Strategy: Results from the Randomized ACUITY Trial” (White, et al)

Wednesday, October 24, 2007
Oral Presentations
Late Breaking Trials
10:50 AM (Main Arena, Ballrooms ABC)	HORIZONS AMI: “A Prospective, Randomized Comparison of Bivalirudin versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction: 30-day Results” (Stone, et al)

11:30 AM (Room 147 AB) TCT-116	TRANSFUSION: “Impact of Transfusion on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention” (Manoukian, et al)
Virtual Posters [Top of page]
All TCT abstracts are available throughout the meeting for complete download as PDF files at specialized TCT Abstract Kiosks throughout the convention center: MAJOR BLEEDING: “Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The ACUITY Trial” (Manoukian, et al) TCT-394 VASCULAR COMPLICATIONS: “Predictors of Major Vascular Access Site Complications in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights from the ACUITY Trial” (Manoukian, et al) TCT-393 GENDER: “Gender Differences in Long-Term Outcomes Following Percutaneous Coronary Intervention of Patients with Non-ST Elevation Acute Coronary Syndrome: Results from the ACUITY Trial” (Lansky, et al) TCT-391 CABG/THIENOPYRIDINE: “Preoperative Thienopyridine Use in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Reduces Adverse Ischemic Events: One-Year Results From the ACUITY Trial” (Ebrahimi, et al) TCT-147

Safety Considerations

ANGIOMAX with provisional use of glycoprotein IIb/IIIa inhibitor is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. ANGIOMAX is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. ANGIOMAX is contraindicated in patients with active major bleeding or hypersensitivity to ANGIOMAX or its components. The most common (

10%) adverse events for ANGIOMAX were back pain, pain, nausea, headache, and hypotension. An unexplained fall in blood pressure or hematocrit, or any unexplained symptom, should lead to serious consideration of a hemorrhagic event and cessation of ANGIOMAX administration. Please see complete prescribing information.